ICON suspends COVID vaccine study after BARDA notice

[A woman using Covid-19 rapid self-test kit at home]
Images By Tang Ming Tung

ICON plc (NASDAQ:ICLR [https://seekingalpha.com/symbol/ICLR]) has announced the suspension of its COVID vaccine study following a stop work notice from BARDA.

The company has ceased all screening and dosing activities for new participants in the trial. However, those already enrolled will continue to receive follow-up care as per the study protocol.

ICON said [https://investor.iconplc.com/static-files/4bbf089c-21e0-4347-a1bb-2ff0af71fe58]that although the stop work order will impact its revenue for the second half of 2025, there is no change to financial guidance for the full year 2025.

MORE ON ICON

* ICON Public Limited Company (ICLR) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4804242-icon-public-limited-company-iclr-q2-2025-earnings-call-transcript]
* ICON: Lower Guidance Downside And Expanded Repurchase Plan [https://seekingalpha.com/article/4803807-icon-plc-lower-guidance-downside-expanded-repurchase-plan]
* ICON: With A 57% Drop, Trump Legislation, And Debt Reduction, Is The Stock Undervalued? [https://seekingalpha.com/article/4797111-icon-stock-57-percent-drop-trump-legislation-debt-reduction-undervalued]
* Icon signals $8B full-year revenue midpoint as metabolic and obesity trial momentum builds [https://seekingalpha.com/news/4471938-icon-signals-8b-full-year-revenue-midpoint-as-metabolic-and-obesity-trial-momentum-builds]
* Icon Q2 2025 Earnings Preview [https://seekingalpha.com/news/4470146-icon-q2-2025-earnings-preview]